GLP-1 Medications Straining Canadian Employer Drug Plans in 2026, Report Finds

The Numbers Behind the Pressure

The Alberta Blue Cross report highlights the stark financial reality for plan sponsors:

• Wegovy (semaglutide 2.4mg) costs approximately $5,000 per patient per year at current Canadian list prices — making it one of the most expensive drugs in the chronic disease management category
• Ozempic (semaglutide for diabetes) costs approximately $3,000–$3,700/year depending on dose
• Mounjaro (tirzepatide), newly covered by some plans, adds further cost at comparable or higher annual rates

Across employer plans that added GLP-1 coverage in 2024–2025, total drug spend in the weight-management category increased by an estimated 300–500% year-over-year, according to the report's aggregate data.

Why Generic Entry Won't Fully Solve the Problem

Many plan sponsors had hoped that the anticipated arrival of generic semaglutide in Canada would significantly reduce costs. The Alberta Blue Cross report tempers those expectations.

"Generic entry will help only at the margins," the report states, citing two key factors:

• Utilization is growing faster than price reductions can offset — as GLP-1 medications become more widely prescribed, the total drug spend continues to rise even as per-unit costs may decrease
• Generic products typically launch at 70–80% of brand-name list prices in Canada, compared to the more dramatic generic discounts seen in the US market, due to Canada's different generic drug pricing framework

Health Canada is currently reviewing generic semaglutide applications from manufacturers including Sandoz, Teva, and Apotex. First generic approvals are anticipated in mid-2026, but market penetration — and meaningful price competition — may take several additional quarters to materialize.

New Indications Are Expanding the Eligible Population

A significant driver of the accelerating cost pressure is the growing list of approved indications for GLP-1 medications. The report specifically flags two new regulatory developments:

• Wegovy approved for MASH (metabolic dysfunction-associated steatohepatitis, also called non-alcoholic fatty liver disease): Health Canada's approval of Wegovy for this indication dramatically expands the population of patients who can receive a prescription on-label. MASH is estimated to affect approximately 1 in 4 Canadians to varying degrees, representing a vastly larger potential patient pool than obesity alone
• Zepbound (tirzepatide) under review for obstructive sleep apnea: Eli Lilly has filed with Health Canada for an additional indication for tirzepatide targeting sleep apnea, a condition affecting an estimated 5–6 million Canadians. If approved, this would further expand GLP-1 eligibility to millions of additional plan members

From a plan design perspective, each new indication creates pressure to cover the drug — since denying coverage for an approved indication can expose employers to human rights or disability accommodation challenges in certain circumstances.

How Employers Are Responding

The Alberta Blue Cross report outlines several strategies plan sponsors are considering or implementing:

• Step therapy requirements — requiring patients to try lower-cost alternatives (such as metformin or older GLP-1 agents like liraglutide) before approving coverage for newer, higher-cost options
• Maximum quantity limits — capping covered doses or requiring annual reauthorization with documented clinical outcomes
• Indication-specific coverage — covering GLP-1s for type 2 diabetes (where clinical evidence is most established) but applying stricter criteria for weight management or other indications
• Preferred drug lists — negotiating preferential pricing with specific manufacturers in exchange for formulary placement

None of these strategies fully eliminates the cost pressure, but together they can reduce total drug spend by an estimated 20–35%, according to the report.

What This Means for Out-of-Pocket Costs

For Canadians with employer benefit plans, the practical impact depends heavily on how their plan responds to this cost pressure:

• Plans that introduce higher cost-sharing ratios for GLP-1 drugs will shift more expense to employees
• Plans that implement maximum dispensing limits may require patients to pay out-of-pocket for higher doses
• Plans that don't cover GLP-1s at all — still a majority of Canadian benefit plans — leave patients to pay the full retail price

Canadians without drug coverage can compare current retail prices across pharmacies at GLP1Prices.ca to find the lowest available price in their province.